Samalin Investment Counsel’s Kyverna Therapeutics KYTX Stock Holding History

Samalin Investment Counsel’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$103K	Buy	+11,595	New	+$103K	0.03%	326

Other funds holding KYTX

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return

GSB Wealth Management Guilford, Connecticut $498M AUM 27.51% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return

Samalin Investment Counsel's KYTX Position: Q2 2026 in Review

Samalin Investment Counsel opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 11,595 shares worth $103K. The stake represents 0.03% of the portfolio and ranks #326 among its holdings.

13 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

Samalin Investment Counsel held 11,595 shares of Kyverna Therapeutics worth $103K as of Q2 2026.
Kyverna Therapeutics was a new Samalin Investment Counsel position in Q2 2026.
Kyverna Therapeutics made up 0.03% of Samalin Investment Counsel's portfolio in Q2 2026, its #326 holding.
13 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Samalin Investment Counsel's 13F filing for Q2 2026, filed 27 Jul 2026.